keyword
MENU ▼
Read by QxMD icon Read
search

Off label psychiatry

keyword
https://www.readbyqxmd.com/read/28702268/distressing-visual-hallucinations-after-treatment-with-trazodone
#1
Gustavo Santos, Ana Maria Moreira
Trazodone, a second-generation atypical antidepressant, is increasingly being used off-label, in the treatment of insomnia. Although generally well tolerated, trazodone treatment can be associated with some complications. We describe a case of a 60-year-old man who received trazodone for primary insomnia. He returned, to the emergency department, two days later with distressing visual hallucinations, which prompted inpatient treatment. Trazodone was discontinued, leading to a complete resolution of his visual hallucinations, and he was treated with mirtazapine for 6 months...
2017: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/28540033/use-of-repeated-intravenous-ketamine-therapy-in-treatment-resistant-bipolar-depression-with-suicidal-behaviour-a-case-report-from-spain
#2
REVIEW
Álvaro López-Díaz, José Luis Fernández-González, José Evaristo Luján-Jiménez, Sara Galiano-Rus, Luis Gutiérrez-Rojas
The rapidly-acting antidepressant properties of ketamine are a trend topic in psychiatry. Despite its robust effects, these are ephemeral and can lead to certain adverse events. For this reason, there is still a general concern around the off-label use of ketamine in clinical practice settings. Nonetheless, for refractory depression, it should be an indication to consider. We report the case of a female patient admitted for several months due to a treatment-resistant depressive bipolar episode with chronic suicidal behaviour...
April 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28430672/lamotrigine-uses-in-psychiatric-practice-beyond-bipolar-prophylaxis-a-hope-or-hype
#3
Ahmed Naguy, Najah Al-Enezi
BACKGROUND: Lamotrigine (LAM), an antiepileptic, with panoply of indications and uses in neurology, is FDA approved, in psychiatry, for bipolar prophylaxis. Apart from this indication, trend of its use in psychiatry is on the rise addressing a multitude of disorders. STUDY QUESTION: LAM remains one of only few psychotropic drugs with antiglutamate activity. This might render LAM a potential therapeutic option in treatment-resistant major psychiatric disorders. We reviewed LAM pharmacology and its diverse indications while examining the extant evidence...
April 19, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28164355/analysis-of-the-appropriateness-of-off-label-antipsychotic-use-for-mental-health-indications-in-a-veteran-population
#4
Jacob T Painter, Richard Owen, Kathy L Henderson, Mark S Bauer, Dinesh Mittal, Teresa J Hudson
STUDY OBJECTIVE: A substantial proportion of antipsychotic (AP) use in veterans is for nonapproved indications (i.e., off-label prescribing). Not all off-label use is necessarily detrimental to patients, however, and in certain situations, off-label prescribing could be considered justifiable. The objective of this study was to determine the extent to which off-label AP prescribing in a veteran population was potentially appropriate. DESIGN: Expert panel and retrospective analysis...
April 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/27737474/pharmacotherapy-in-psychiatric-disorders-of-children-current-evidence-and-trends
#5
M Kölch, P L Plener
Pharmacotherapeutic interventions are available for most psychiatric disorders in children. Evidence for these interventions varies, depending on the targeted disorders. For attention-deficit/hyperactivity disorder, a sound database on efficacy and safety of medication exists. For other common disorders or psychopathological phenomena like disruptive behavior, anxiety disorders, depressive disorders, or autism, data on efficacy and safety are much scarcer. This selective review aims to provide an overview about current psychopharmacological interventions in child and adolescent psychiatry...
November 2016: Pharmacopsychiatry
https://www.readbyqxmd.com/read/27711942/reversible-valproic-acid-induced-parkinsonism-and-cognitive-impairment-in-an-elderly-patient-with-bipolar-disorder-i
#6
Sameer Hassamal, Susan Waller, Kimberly Reese, Claudia Testa
Valproic acid (VPA) is approved by the Food and Drug Administration (FDA) for the treatment of manic or mixed episodes associated with bipolar disorder. VPA is also used off-label to treat other conditions in psychiatry such as impulse control disorders, major depression, and posttraumatic stress disorder (PTSD). Although VPA is mostly well-tolerated, common adverse effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), neurological symptoms (sedation, ataxia, tremor), weight gain, and alopecia...
2016: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://www.readbyqxmd.com/read/27551945/therapeutic-drug-monitoring-as-a-measure-of-proactive-pharmacovigilance-in-child-and-adolescent-psychiatry
#7
REVIEW
Manfred Gerlach, Karin Egberts, Su-Yin Dang, Paul Plener, Regina Taurines, Claudia Mehler-Wex, Marcel Romanos
Off-label or unlicensed use of psychotropic drugs is common rather than the exception in child and adolescent psychiatry. This use exposes patients to an unknown additional risk of ineffective or even harmful treatment. In addition, treatment with psychotropic drugs during a period of life when the patient undergoes marked developmental hormonal and neurobiological changes often requires different dosing regimes in later life and may result in adverse drug reactions, which are either not seen in adults at all or not in the same frequency...
November 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27529772/off-label-prescription-of-psychopharmacological-drugs-in-child-and-adolescent-psychiatry
#8
Julie Vestergaard Braüner, Lily Manzello Johansen, Troels Roesbjerg, Anne Katrine Pagsberg
This study aimed to describe the frequency of off-label prescriptions of psychopharmacological drugs in a child and adolescent psychiatric setting. A cross-sectional study was conducted on November 1, 2014, including all inpatients and outpatients at the Mental Health Centre for Child and Adolescent Psychiatry, Capital Region of Denmark, aged 0 to 17 years receiving medical treatment with antidepressants, antipsychotic agents, benzodiazepines, melatonin and/or attention deficit hyperactivity disorder (ADHD) medication...
October 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27098018/bap-position-statement-off-label-prescribing-of-psychotropic-medication-to-children-and-adolescents
#9
EDITORIAL
Aditya N Sharma, Celso Arango, David Coghill, Paul Gringras, David J Nutt, Peter Pratt, Allan H Young, Chris Hollis
The off-label use of medicines for children and adolescents remains a common and important issue for prescribing practice across child and adolescent psychiatry, paediatrics and primary care. This editorial focusses on psychotropic drug treatment, which plays an essential part in the comprehensive management of a range of child and adolescent psychiatric disorders. Despite a growing evidence base for drug treatment in child and adolescent psychiatric disorders, much psychotropic medication continues to be prescribed off-label (i...
May 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/26260136/off-label-prescribing-by-psychiatrists-what-is-the-practitioner-s-liability
#10
Christophe Bartoli, Caroline Berland-Benhaim, Caroline Sastre, Valerie Baillif-Couniou, Pascal Kintz, Georges Leonetti, Anne-Laure Pelissier-Alicot
In psychiatry, the molecules available and the dosages recommended when a drug receives marketing authorization are not always adequate to treat patients with major behavioral disturbances. Off-label prescribing is frequent in this context, with regard to the indications and the dosages given as well as to the drug combinations used. However, if complications or death occur, the practitioner's liability may be engaged. The authors report three deaths attributed to off-label prescribing in psychiatry and which led to charges against the physicians...
November 2015: Journal of Forensic Sciences
https://www.readbyqxmd.com/read/26166453/unmet-needs-in-paediatric-psychopharmacology-present-scenario-and-future-perspectives
#11
REVIEW
Antonio M Persico, Celso Arango, Jan K Buitelaar, Christoph U Correll, Jeffrey C Glennon, Pieter J Hoekstra, Carmen Moreno, Benedetto Vitiello, Jacob Vorstman, Alessandro Zuddas
Paediatric psychopharmacology holds great promise in two equally important areas of enormous biomedical and social impact, namely the treatment of behavioural abnormalities in children and adolescents, and the prevention of psychiatric disorders with adolescent- or adult-onset. Yet, in striking contrast, pharmacological treatment options presently available in child and adolescent psychiatry are dramatically limited. The most important currently unmet needs in paediatric psychopharmacology are: the frequent off-label prescription of medications to children and adolescents based exclusively on data from randomized controlled studies involving adult patients; the frequent lack of age-specific dose, long-term efficacy and tolerability/safety data; the lack of effective medications for many paediatric psychiatric disorders, most critically autism spectrum disorder; the scarcity and limitations of randomized placebo-controlled trials in paediatric psychopharmacology; the unexplored potential for the prevention of psychiatric disorders with adolescent- and adult-onset; the current lack of biomarkers to predict treatment response and severe adverse effects; the need for better preclinical data to foster the successful development of novel drug therapies; and the effective dissemination of evidence-based treatments to the general public, to better inform patients and families of the benefits and risks of pharmacological interventions during development...
October 2015: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/26103533/experiences-with-patient-refusal-of-off-label-prescribing-of-psychotropic-medications-to-children-and-adolescents-in-japan
#12
Noa Tsujii, Takuya Saito, Yuji Izumoto, Masahide Usami, Takashi Okada, Hideki Negoro, Junzo Iida
OBJECTIVE: In child and adolescent psychiatry, the off-label prescribing of psychotropic medications is common. The purpose of this study was to examine the experiences of Japanese child and adolescent psychiatrists with off-label prescribing to children and/or adolescents (hereafter referred to as "children") and to identify the factors associated with these experiences. METHODS: A prospective questionnaire was sent to 1628 psychiatrists belonging to the Japanese Society for Child and Adolescent Psychiatry...
September 2016: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/26012242/reasons-for-and-frequency-of-off-label-drug-use
#13
Svetlana Goločorbin Kon, Ivana Iliković, Momir Mikov
INTRODUCTION: The application of drugs in accordance with the marketing authorization issued by the regulatory authority is considered on-label use, while off-label drug use frequently occurs in medical practice. It includes the application of drugs beyond approved indications; for unapproved age group, with different dosage regimens or different administration route. Medical specialists frequently prescribe an off-label drug in pediatrics, neonatology, geriatrics, psychiatry and oncology...
January 2015: Medicinski Pregled
https://www.readbyqxmd.com/read/25951625/-hyperkinetic-disorders-in-childhood-and-adolescence-an-analysis-of-kinderagate-2009-2012
#14
COMPARATIVE STUDY
Benedikt Stegmann, Christian A Rexroth, Katharina Wenzel-Seifert, Ekkehard Haen
OBJECTIVE: This contribution evaluates the prevalence, medication use as well as age and sex distribution in inpatients with hyperkinetic disorders at the KinderAGATE hospitals for 2009-2012. METHOD: The age, sex, leading diagnosis, prescribed medication, and dosage of each patient were recorded anonymously twice a year. They provide an outstanding epidemiological basis for the observation of the actual situation in child and adolescent psychiatry. RESULTS: Compared to our patient collective, patients diagnosed with hyperkinetic disorders (25...
March 2015: Zeitschrift Für Kinder- und Jugendpsychiatrie und Psychotherapie
https://www.readbyqxmd.com/read/25817088/-use-of-valproic-acid-in-long-stay-units-of-psychiatry
#15
M Teresa Martínez-Lazcano, Sara Esplá-González, Paola Herraiz-Robles, Pilar Hernández-Pérez, Raquel Chillerón-Cuenca, Emilio Pol-Yanguas
OBJECTIVE: Valproic acid is often used in psychiatry to treat schizophrenia and other conditions outside of indication ("off-label"). However, its effectiveness has not been sufficiently demonstrated and its use is not exempt of adverse effects. This study's main objective is to determine the frequency of use of valproic acid in approved indications and the "off-label" use in psychiatric patients. METHODS: A cross-sectional study on July 7, 2014 with a sample of 167 patients residents in a psychiatric center was designed...
March 1, 2015: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/25767363/off-label-drug-use-in-psychiatry-outpatient-department-a-prospective-study-at-a-tertiary-care-teaching-hospital
#16
Darshan Kharadi, Kamlesh Patel, Devang Rana, Varsha Patel
INTRODUCTION: Off-label drug prescribing is very common in Psychiatry. US-Food and Drug Administration has defined off-label drug as "use of drugs for the indication, dosage form, regimen, patient or other use constraint not mentioned in the approved labeling." OBJECTIVE: The objective was to evaluate off-label drug use in patients attending Outpatient Department of Psychiatry. MATERIALS AND METHODS: One year prospective, cross sectional study was conducted on patients attending Psychiatry Outpatient Department...
March 2015: Journal of Basic and Clinical Pharmacy
https://www.readbyqxmd.com/read/25406048/predictors-of-polypharmacy-and-off-label-prescribing-of-psychotropic-medications-a-national-survey-of-child-and-adolescent-psychiatrists
#17
Marcia A Kearns, Kristin M Hawley
We employed a national survey of child psychiatrists to examine typical prescribing practices for children with anxiety, depression, and disruptive behavior disorders. We examined the extent to which polypharmacy and off-label prescribing occur in routine practice and the degree to which child characteristics, child psychiatrist characteristics, and medication availability may influence these prescribing practices. We found that child psychiatrists most often prescribed medications that were on-label according to U...
November 2014: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/25335522/pediatric-psychopharmacological-research-in-the-post-eu-regulation-1901-2006-era
#18
Christine Schmäl, Katja Becker, Ruth Berg, Michael Brünger, Gerd Lehmkuhl, Klaus-Ulrich Oehler, Thorsten Ruppert, Claus Staudter, Götz-Erik Trott, Ralf W Dittmann
Although the use of psychotropic medications in child and adolescent psychiatry in Germany is on the increase, most compounds are in fact prescribed "off-label" because of a lack of regulatory approval in these age groups. In 2007, the European Parliament introduced Regulation 1901/2006 concerning medicinal products in pediatric populations, with a subsequent amendment in the form of Regulation 1902/2006. The main aim of this legislation was to encourage research and clinical trials in children and adolescents, and thus promote the availability of medications with marketing authorization for these age groups...
November 2014: Zeitschrift Für Kinder- und Jugendpsychiatrie und Psychotherapie
https://www.readbyqxmd.com/read/25154009/antipsychotic-use-in-children-and-adolescents-a-1-year-follow-up-study
#19
Inmaculada Baeza, Elena de la Serna, Rosa Calvo-Escalona, Astrid Morer, Jessica Merchán-Naranjo, Cecilia Tapia, Ma Carmen Martínez-Cantarero, Patrícia Andrés, José A Alda, Bernardo Sánchez, Celso Arango, Josefina Castro-Fornieles
OBJECTIVE: The objective of this study was to analyze the initial treatment with antipsychotics (APs) and its changes during the first year of treatment in patients visited in specialized child and adolescent psychiatry departments. METHODS: Participants were 265 patients, aged 4 to 17 years, who attended consecutively at 4 different centers and were naive of AP or quasi-naive (less than 30 days since the beginning of AP treatment). Type of AP, dosage, and concomitant medication were registered at baseline, 1, 3, 6, and 12 months after beginning the treatment with AP...
October 2014: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/25126291/use-pattern-and-off-label-use-of-atypical-antipsychotics-in-bipolar-disorder-1998-2002
#20
Jeffery A Demland, Yonghua Jing, Christina M L Kelton, Jeff J Guo, Hong Li, Patricia R Wigle
BACKGROUND: Postmarketing surveillance that identifies patients at high risk for receiving off-label medications will help ensure that the benefits of such treatment outweigh the risks. Because many off-label uses have little scientific support, tracking the extent to which they occur as well as the particular circumstances under which they occur is important. OBJECTIVE: To describe the drug-use pattern for patients with bipolar disorder, and to identify demographic and clinical factors associated with off-label use of atypical antipsychotics before US Food and Drug Administration approval for this indication...
June 2009: American Health & Drug Benefits
keyword
keyword
97307
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"